EU researchers developed a candidate drug that blocks vascular inflammation, reducing the risk of cardiovascular disease (CVD) in patients. A second EU-funded initiative worked to further develop and register this drug for clinical application.
Studies have shown that low levels of antibodies to phosphorylcholine (anti-PC) can indicate a higher risk for development of CVD as well as complications in existing patients. Therefore, the EU initiative CVDIMMUNE developed the candidate drug PC-mAb, an innovative fully human monoclonal antibody that can block vascular inflammation.
Further details: New therapeutic antibody for hearts-in-distress